A Phase 2 interventional study of Low-Dose Naltrexone and Acetaminophen Combination and Placebo in Migraine With or Without Aura, sponsored by Allodynic Therapeutics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-10.
Sponsored by Allodynic Therapeutics, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing acetaminophen in Headache — 1 open to participants now, 1 under way, 1 of them phase 3. Acetaminophen · Headache.
Among the 11 studies testing acetaminophen in Headache, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is the only one in phase 2, and was the 7th registered.
762 studies on the registry are indexed under Headache; 134 are open to participants now.
Browse Headache studies →1 of the 11 studies testing acetaminophen in Headache is open now. Recruiting first, the newest first:
Assiut University
Ages 18–65
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 65 across 560 interventional studies indexed under Headache.
Median enrollment 80 across the 11 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 10 most frequent:
Allodynic Therapeutics, Inc is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Allodynic Therapeutics, Inc has 1 study filed under Headache — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing acetaminophen in Headache, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Low-Dose Naltrexone and Acetaminophen Combination
Drug: Placebo
Drug pages: Naltrexone · Acetaminophen
Twice daily
Twice daily
Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period.
Migraine with or without aura is defined according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version). Migraine headaches must be moderate or severe and lasting ≥30 minutes. When the patient falls asleep during migraine and wakes up without it, duration of the attack is reckoned until the time of awakening).
Time frame: From the 28-day baseline period to the last 28 days of the 84-days double-blinded treatment period.
The Number of Participants With More Than 50% Improvement in the Mean Monthly Migraine Days (MMDs)
MMD stands for change in Monthly Migraine Days from 28-day baseline to the last 28 days of the double-blind treatment period
Time frame: From the 28-day baseline period to the last 28 days of the 84-days double-blinded treatment period.
The Number of Participants With More Than 75% Improvement in the Mean Monthly Migraine Days (MMDs)
Time frame: From the28-day baseline period to the last 28 days of the 84-day treatment period.
The Number of Participants With 100% Improvement in Mean MMD in the Last 28 Days Double-blinded Treatment Period.
Time frame: From the 28-day baseline period to the last 28 days of the 84-day treatment period.
Mean Monthly Acute Migraine Medication Treatment Days Change From Baseline to Last 28 Days of Treatment
Time frame: From the 28-day baseline period to the last 28 days of the 84-day treatment period.
The Change in HIT-6 From Baseline to Last 28 Days of Treatment
HIT-6 - headache impact test - was designed to provide a global measure of adverse headache impact. Score range is 36-78, Score ≥ 60 - a very severe impact on life, scored ≤ 49 little to no impact on life. The percent responders were calculated as follows: the change from baseline score divided by the score at the baseline minus 36.
Time frame: From the 28-day baseline period to the last 28 days of the 84-day treatment period.
The Change in Mean PIRS-20 From Baseline to Last 7 Days of Treatment.
Average of PIRS-20, (0-60 = higher with difficulty with sleep)
Time frame: From baseline to month 3 of the treatment period.
The Number of Participants Who Had an Improvement in Patient Global Impression of Change (PGIC) at End of Treatment
Time frame: From baseline to month 3 of the treatment period.
The Number of Participants Reporting Patients' Satisfaction Level
Time frame: From baseline to month 3 of the treatment period.
Mean Monthly Migraine Hours Change From Baseline to Last 28 Days of Treatment
Time frame: From baseline to month 3 of the treatment period.
Change in at Least Moderate Migraine Days in Treatment
Time frame: From baseline to month 3 of the treatment period
The Number of Participants Who Achieved the Percentage of Response in at Least Moderate Migraine Days Baseline to Last 28 Days of Treatment
Time frame: From baseline to month 3 of the treatment period.
Mean Severe Headache Days Change From Baseline to Last 28 Days of Treatment
Time frame: From baseline to month 3 of the treatment period.
Patient recruitment was conducted in a single site in Miami, Florida.
| Milestone | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
Migraine with or without aura is defined according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version). Migraine headaches must be moderate or severe and lasting ≥30 minutes. When the patient falls asleep during migraine and wakes up without it, duration of the attack is reckoned until the time of awakening).
| days | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period. | -5.67 ± 3.2 | -3.5 ± 5.56 |
MMD stands for change in Monthly Migraine Days from 28-day baseline to the last 28 days of the double-blind treatment period
| Participants | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| The Number of Participants With More Than 50% Improvement in the Mean Monthly Migraine Days (MMDs) | 4 | 2 |
| Participants | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| The Number of Participants With More Than 75% Improvement in the Mean Monthly Migraine Days (MMDs) | 4 | 1 |
| Participants | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| The Number of Participants With 100% Improvement in Mean MMD in the Last 28 Days Double-blinded Treatment Period. | 3 | 1 |
| days | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| Baseline acute number of migraine medication treatment days | 7.67 ± 2.07 | 8.67 ± 3.5 |
| Acute migraine medication treatment days in last 28 days of treatment period | 2.67 ± 4.32 | 5.5 ± 3.27 |
| change in monthly acute migraine medication treatment days baseline to last 28 days of treatment | -5 ± 5.37 | -3.17 ± 5.49 |
HIT-6 - headache impact test - was designed to provide a global measure of adverse headache impact. Score range is 36-78, Score ≥ 60 - a very severe impact on life, scored ≤ 49 little to no impact on life. The percent responders were calculated as follows: the change from baseline score divided by the score at the baseline minus 36.
| score | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| Baseline (Randomization visit) mean HIT-6, score | 68.5 ± 5.68 | 68.83 ± 5.27 |
| HIT-6 in last 28 days of treatment, score | 47.83 ± 17.69 | 58 ± 12.08 |
| The change in HIT-6 from baseline to last 28 days of treatment, score | -20.67 ± 19.08 | -10.83 ± 12.98 |
Average of PIRS-20, (0-60 = higher with difficulty with sleep)
| score | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| Baseline (Randomization visit) mean PIRS-20, score | 32.67 ± 16.97 | 31.83 ± 7.03 |
| PIRS-20 in last week of treatment period, score | 10 ± 19.32 | 20.83 ± 14.39 |
| The change in PIRS-20 from baseline to last week of treatment, score | -22.67 ± 22.64 | -11 ± 8.92 |
| Participants | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| PGIC, Change≥2 points, (%) | 4 | 2 |
| PGIC, Change=3 points, (%) | 4 | 2 |
| Participants | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| Satisfied or very satisfied (level 2 or 3) | 4 | 2 |
| Very satisfied (level 3) | 4 | 2 |
| Hours | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| Baseline, hours | 70.78 ± 47.6 | 54.44 ± 36.21 |
| Monthly migraine hours in last 28 days of treatment, hours | 24.65 ± 35.23 | 37.07 ± 38.05 |
| The change in monthly migraine hours from baseline to last 28 days of treatment, hours | -46.13 ± 59.44 | -17.37 ± 41.11 |
| days | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| Mean monthly at least moderate Headaches days at baseline | 8.33 ± 2.73 | 9 ± 2.45 |
| Mean at least moderate migraine days in the last 28 days of the treatment period | 3.67 ± 5.57 | 6.17 ± 4.54 |
| The change in at least moderate migraine days from baseline to the last 28 days of treatment period | -4.78 ± 4.42 | -2.83 ± 5.74 |
| Participants | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| ≥50% | 4 | 2 |
| ≥75% | 4 | 1 |
| ≥90% | 3 | 1 |
| 100% | 3 | 1 |
| days | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| Mean monthly severe headaches days at baseline | 4.83 ± 1.72 | 4.33 ± 2.88 |
| Mean severe headache days in the last 28 days of the treatment period | 2.67 ± 3.93 | 2.5 ± 3.02 |
| The change in severe headache days from baseline to the last 28 days of the treatment period | -2.17 ± 2.79 | -1.83 ± 3.87 |
Collected over One month follow-up after 3 months of treatment. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low-Dose Naltrexone and Acetaminophen Combination | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Low-Dose Naltrexone and Acetaminophen Combination | Placebo |
|---|---|---|
| Dry MouthGeneral disorders | 1/6 | 0/6 |
| FatigueGeneral disorders | 1/6 | 1/6 |
| Gastroesophageal RefluxGastrointestinal disorders | 1/6 | 0/6 |
| Heavy BreathingGeneral disorders | 1/6 | 1/6 |
| NauseaGeneral disorders | 1/6 | 0/6 |
| PalpitationsGeneral disorders | 1/6 | 0/6 |
| SomnolenceGeneral disorders | 1/6 | 1/6 |
| VomitingGeneral disorders | 1/6 | 0/6 |
Baseline analysis population included all treated participants (all enrolled participants who took the study drug).
| Age, Categorical(Participants) | Low-Dose Naltrexone and Acetaminophen Combination | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 12 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Low-Dose Naltrexone and Acetaminophen Combination | Placebo | Total |
|---|---|---|---|
| Mean | 41.5 ± 14.3 | 39 ± 10.4 | 40 ± 12 |
| Sex: Female, Male(Participants) | Low-Dose Naltrexone and Acetaminophen Combination | Placebo | Total |
|---|---|---|---|
| Female | 4 | 6 | 10 |
| Male | 2 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Low-Dose Naltrexone and Acetaminophen Combination | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 8 |
| Not Hispanic or Latino | 2 | 2 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Low-Dose Naltrexone and Acetaminophen Combination | Placebo | Total |
|---|---|---|---|
| Caucasian | 6 | 5 | 11 |
| African American | 0 | 1 | 1 |
| Region of Enrollment(participants) | Low-Dose Naltrexone and Acetaminophen Combination | Placebo | Total |
|---|---|---|---|
| United States | 6 | 6 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Jul 2018, 11 months.
Results were first posted in Apr 2024, 5 years 8 months after primary completion.
Of 31 phase 2 interventional studies under Headache, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naltrexone · Acetaminophen
Allodynic Therapeutics, Inc